Detailed entry information

Protein Information (annotations from UniProt)

Database IDHIV0003796
UniProt IDO15145
Primary gene name(s)ARPC3
Synonym gene name(s)ARC21
Protein nameActin-related protein 2/3 complex subunit 3
Protein functionFunctions as component of the Arp2/3 complex which is involved in regulation of actin polymerization and together with an activating nucleation-promoting factor, NPF mediates the formation of branched actin networks.
Subcellular locationCytoplasm, cytoskeleton. Cell projection.
ECO codeClick here for more information.
Amino acid sequence
FASTA format: O15145
Gene Ontology
(Biological Process)
Complete annatation
Arp2/3 complex-mediated actin nucleation [GO:0034314];
cellular response to nerve growth factor stimulus [GO:1990090];
ephrin receptor signaling pathway [GO:0048013];
Fc-gamma receptor signaling pathway involved in phagocytosis [GO:0038096];
movement of cell or subcellular component [GO:0006928]
Gene Ontology
(Molecular Function)
Complete annatation
structural constituent of cytoskeleton [GO:0005200]
Gene Ontology
(Cellular Component)
Complete annatation
actin cytoskeleton [GO:0015629];
Arp2/3 protein complex [GO:0005885];
cytosol [GO:0005829];
extracellular exosome [GO:0070062];
focal adhesion [GO:0005925];
lamellipodium [GO:0030027];
membrane [GO:0016020]
Protein-protein interaction115401
Phylogenetic treeO15145
HIV replication factor status Zhou et al., Cell. Host. Microbe., 2008
      unknown
Brass et al., Science, 2008
      unknown
Smith et al., J. Immunol, 2010
      unknown
Interferon-stimulated
gene status
Lu et al., J. Virol., 2011
      Folds changes 8h: unknown; Folds changes 16h: unknown; Tested: unknown;
Schoggins JW and Rice CM, Curr. Opin. Virol., 2011
      Targeted viruses: unknown
      Viral life cycle: unknown
      Mechanism related to antiviral activity: unknown
Anti-viral restriction factor Liu et al., Retrovirology, 2011
      unknown (Triplicates)

Gene Expression Profile       top

            Up-regulated;            Down-regulated

For brief introduction to each study, please go to the help page.

Gene expression during HIV latency

(1). Mohammadi et al., PLoS Pathog., 2014

Differentially expressed transcripts (Pairwise) during latency and subsequent viral reactivation using several agents - Primary CD4+ T-cell based model


DMSO: Dimethyl suloxyde (negative control) - 0.0033% final
SAHA: Vorinostat (Histone deacetylase inhibitor) - 0.5 μM
CD3: TCR Stimulation by IL-2+ antiCD3/anti-CD28 antibodies
IL7: Interleukin-7 based stimulation
DISU: Disulfiram (alcohol dehydrogenase inhibitor) - 0.5 μM
AZA: 5-azacytidine (AZA; DNA methylation inhibitor) - 1 μM
Experimental Condition Log2 Fold Change P value Adjusted P value
AZA vs. CD30.165125464938530.6153300977709420.717321930049009
AZA vs. DISU-0.2192325392077360.3854820214201880.90058897815532
AZA vs. IL70.132908019633820.4880753962302760.999311006273513
AZA vs. SAHA-0.5218516979403650.0328666078102040.209928494123312
DISU vs. CD3-0.3973214429374430.2769277853369480.406070956825794
DISU vs. IL70.3430192680721920.1730873363789870.538664656464332
DISU vs. SAHA-0.3010001831821660.3033766594534180.687451442937339
DMSO vs. AZA-0.08540597034292240.6088960347716561
DMSO vs. CD3-0.2619767829663720.4151477263294050.529388902755416
DMSO vs. DISU0.1320410989596030.5876677920577930.934701463289767
DMSO vs. IL70.2254819058342040.208672678661710.717686982288547
DMSO vs. SAHA-0.4427284475883170.06109985891573460.283850743229236
HIV vs. Mock in Activation-0.2927676877260980.6377231115985310.999983755607037
HIV vs. Mock in Latency-0.003435944080443520.9833449687606980.999834320637052
IL7 vs. CD3-0.02451835375270780.9393047321980780.961960879767742
SAHA vs. CD3-0.7114162993622130.0448474071678060.0907098451958881
SAHA vs. IL7-0.6576235147828070.007128430390019760.0495179537784137
(2). Iglesias-Ussel et al., J. Virol., 2013

Up and Downregulated transcripts during Latency (Latently infected CD4+ T cells vs Uninfected)- Primary CD4+Tcell based model
Log2 Fold Change P Value
unknown unknown

Gene expression during HIV infection and replication

(1). Imbeault et al., PloS Pathog., 2012

Transcriptomic profiling of HIV-1 infected CD4+ T cells - Primary CD4+ T cells
Experiment type Log2 Fold Change P Value Adjusted P Value
Infected vs. Mock unknown unknown unknown
Infected vs. Bystander unknown unknown unknown
(2). Lefebvre et al., J. Virol., 2011

Transcriptome analysis of T-cell line (Sup T1)
Log2 Fold Change unknown
(3). Li et al., J. Immunol., 2013

Lymphatic tissue
Acute Fold Change Acute P Value Asymt Fold Change Asypt P Value AIDS Fold Change AIDS P Value
unknown unknown unknown unknown unknown unknown
(4). Chang et al., MBio., 2011

Transcriptome analysis of T-cell line (Sup T1)

Derived from Sherrill-Mix et al., BMC Retrovirol., 2015 cross validation
Up-regulated (True) unknown
(5). Sherrill-Mix et al., BMC Retrovirol., 2015

Deep RNA-seq analysis of primary human T cell infected with low passage HIV isolate HIV89.6 - Primary CD4+ T cell based
Test Status Log2 Fold Change P Value
OK -0.0792734 0.643941
(6). Rotger et al., PLoS Pathog., 2010

Genome-wide mRNA expression of CD4+ T cells from HIV-infected patient
(Genes differentially expressed (at adjusted p<0.01) according to the empirical Bayes approach)
Log2 Fold Change P Value
unknown unknown

Proteomic/Transcriptomics studies indicating differentially expressed genes mediated by HIV

(1). Greenwood et al., Elife, 2016

Activated (CD3/CD28) Primary human CD4+ T cells infected with pNL4-3-dE-EGFP. The table shows the complete (unfiltered) TMT (tandem mass tag)-based proteomic time course dataset
6 h 24 h 48 h 72 h RTi
0.99 1.036 0.986 1.042 1.103
(2). Navare et al., Virology, 2012

SUP-T1 cell line
FC-4hpi P-value FC-8hpi P-value FC-20hpi P-value Category
unknown unknown unknown unknown unknown unknown unknown
(3). Hyrcza et al., J. Virolo., 2007

Primary human CD4+ and CD8+ T Cells
Affymetrix Prob ID Fold Change In CD8? Category
unknown unknown unknown unknown

Protein Overview       top

Drug-protein Interaction       (annotations from DrugBank)      top

Drugbank ID Drug Name Drug Status Pharmacological Action Drug Action
DB08235 N-[2-(2-methyl-1H-indol-3-yl)ethyl]thiophene-2-carboxamide experimental unknown unknown
DB08236 (2S)-2-(3-bromophenyl)-3-(5-chloro-2-hydroxyphenyl)-1,3-thiazolidin-4-one experimental unknown unknown

Protein Secondary Structure       (annotations from PDB)      top

not found

HIV-1 Interaction       (annotations from NCBI HIV-1 Interaction Database)      top

not found

Metabolic/Signalling Pathway       (annotations from KEGG database)      top

Pathway Accession Number Description
hsa04144 Endocytosis - Homo sapiens (human)
hsa04666 Fc gamma R-mediated phagocytosis - Homo sapiens (human)
hsa04810 Regulation of actin cytoskeleton - Homo sapiens (human)
hsa05100 Bacterial invasion of epithelial cells - Homo sapiens (human)
hsa05130 Pathogenic Escherichia coli infection - Homo sapiens (human)
hsa05131 Shigellosis - Homo sapiens (human)
hsa05132 Salmonella infection - Homo sapiens (human)
Menu